Access to affordable healthcare: Fresenius Kabi supports Global Biosimilars Week

November 18, 2020

Access to affordable healthcare: Fresenius Kabi supports Global Biosimilars Week

Driven by its corporate philosophy of caring for life, Fresenius Kabi is committed to providing lifesaving medicines and technologies to critically and chronically ill patients around the world. With its biosimilar products, the company unlocks the potential of high-quality therapies for even more patients, increasing access to affordable, state-of-the-art healthcare.

To further raise awareness for biosimilars and their impact on patients’ quality of life around the world, Fresenius Kabi supports the Global Biosimilars Week: From November 16 to 20, 2020, the company will share interesting information on biosimilars and how patients are treated with these biologic drugs. The awareness week will provide insights into the experiences of healthcare professionals who are using biosimilars in patient care.

Fresenius Kabi attaches great importance to the further development of biosimilars. In its research and patient care, the company focuses on autoimmune diseases such as rheumatoid arthritis as well as oncology treatments. In 2019, Fresenius Kabi launched its first biosimilar product, an adalimumab biosimilar that facilitates more patient access to effective treatment options in the areas of rheumatology, gastroenterology and dermatology.  

“The launch of our first biosimilar was an important milestone in our longstanding tradition of putting patients first and providing them access to high-quality treatments. Meanwhile, we have made the product available in several European countries and successfully started a cooperation in Germany with the pharmaceutical company medac in the area of rheumatic illnesses,” said Dr. Michael Schönhofen, President Pharmaceuticals and Devices Division of Fresenius Kabi.

In 2020, the regulatory submissions for Fresenius Kabi’s biosimilar candidate of pegfilgrastim have been accepted for review both by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) – another step forward in the company’s commitment to affordable healthcare. Learn more about affordable state-of-the-art therapies for an increasing number of patients on Fresenius Kabi’s dedicated biosimilars webpage. Further information about the Global Biosimilars Week can be found on the website of the International Generic and Biosimilar Medicines Association, which organizes this initiative.